Glaukos (GKOS) Competitors

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Which has higher valuation & earnings, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$383.48M	14.06	-$134.66M	-$2.87	-32.90
Zimmer Biomet	$7.68B	2.66	$903.70M	$4.45	23.16

Do insiders & institutionals have more ownership in GKOS or ZBH?

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 6.4% of Glaukos shares are owned by company insiders. Comparatively, 1.0% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer GKOS or ZBH?

Zimmer Biomet received 452 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.09% of users gave Zimmer Biomet an outperform vote while only 65.18% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 453 65.18%	Underperform Votes 242 34.82%
Zimmer Biomet	Outperform Votes 905 67.09%	Underperform Votes 444 32.91%

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Glaukos' net margin of -39.04%. Zimmer Biomet's return on equity of 12.99% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-39.04%	-16.53%	-10.61%
Zimmer Biomet	11.77%	12.99%	7.58%

Does the media prefer GKOS or ZBH?

In the previous week, Zimmer Biomet had 3 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for Zimmer Biomet and 13 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.48 beat Glaukos' score of 0.98 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	15 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, GKOS or ZBH?

Glaukos has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Do analysts rate GKOS or ZBH?

Glaukos currently has a consensus target price of $156.17, suggesting a potential upside of 65.40%. Zimmer Biomet has a consensus target price of $124.15, suggesting a potential upside of 20.46%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.32

Summary

Zimmer Biomet beats Glaukos on 11 of the 19 factors compared between the two stocks.